On September 27, 2019, the U.S. Food and Drug Administration (FDA) replied to MAPS’ complete response to the partial clinical hold placed on Study MT2 by issuing a Continued Partial Clinical Hold Letter, citing the same concerns as the initial letter and concluding that the issues had not been sufficiently resolved.